FindTrial
Sign In

To identify blood based biomarker to predict lupus flare using molecular and protein marker

An integrated transcriptomics and proteomics approach for identification of altered plasma miRNA and blood proteins as composite biomarker panel in lupus flare - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/071185
Enrollment
50
Registered
2024-07-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M048- Other autoinflammatory syndromes

Interventions

Control Intervention1: NIL: NIL

Sponsors

Indian Rheumatology Association
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: SLE patients with mild or severe flare Patients conformed to the SLE classification criteria by the 2019 EULAR/ACR classification Female or male above 18 years

Exclusion criteria

Exclusion criteria: Pregnant women Malignant Patients Patients with other autoimmune disease Patients with comorbidities

Design outcomes

Primary

MeasureTime frame
1. To develop miRNA characterization and blood proteomics profiles in lupus at different disease activities. 2. The targeted miRNA-protein pathway will be used to develop novel targeted therapy for lupusTimepoint: 12 months—

Secondary

MeasureTime frame
Identifying specific miRNA and protein-specific pathways from the blood cell will help in screening and early diagnosis, as well as a novel way to monitor precision therapy.Timepoint: 12 months—

Countries

India

Contacts

Public ContactAbhibroto Karmakar

Kasturba Medical College ,Manipal

abhibroto.karmakar@learner.manipal.edu09051469974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026